Get the Stockscreener App
11.01
1.01%
0.11
Pre-market:
11.24
0.23
+2.09%
Certara Inc stock is traded at $11.01, with a volume of 1.10M.
It is up +1.01% in the last 24 hours and down -19.40% over the past month.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
See More
Previous Close:
$10.90
Open:
$11.075
24h Volume:
1.10M
Relative Volume:
0.85
Market Cap:
$1.77B
Revenue:
$363.55M
Net Income/Loss:
$-78.68M
P/E Ratio:
-22.02
EPS:
-0.5
Net Cash Flow:
$50.74M
1W Performance:
-7.56%
1M Performance:
-19.40%
6M Performance:
+2.71%
1Y Performance:
-41.56%
1-Day Range:
$10.82
$11.24
1-Week Range:
$10.79
$12.04
52-Week Range:
$9.41
$19.29
Certara Inc Stock (CERT) Company Profile
Name
Certara Inc
Sector
Industry
Phone
(415) 237-8272
Address
4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR
Compare CERT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERT
Certara Inc
|
11.01 | 1.77B | 363.55M | -78.68M | 50.74M | -0.50 |
|
VEEV
Veeva Systems Inc
|
233.46 | 37.90B | 2.75B | 714.14M | 1.09B | 4.33 |
|
SOLV
Solventum Corp
|
74.01 | 12.80B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
DOCS
Doximity Inc
|
64.30 | 12.07B | 516.85M | 174.11M | 217.38M | 0.87 |
|
HQY
Healthequity Inc
|
95.78 | 8.30B | 1.15B | 96.70M | -161.99M | 1.09 |
|
TEM
Tempus Ai Inc
|
45.50 | 7.84B | 640.44M | -743.28M | -206.93M | -11.29 |
Certara Inc Stock (CERT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Upgrade | UBS | Neutral → Buy |
| Apr-10-24 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Apr-04-24 | Initiated | JMP Securities | Mkt Perform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | UBS | Neutral |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Aug-22-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-10-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-23 | Initiated | Stephens | Overweight |
| Apr-03-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-08-22 | Initiated | Berenberg | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-01-22 | Initiated | Piper Sandler | Overweight |
| Jan-11-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Jul-23-21 | Initiated | Robert W. Baird | Outperform |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-06-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Neutral |
| Jan-05-21 | Initiated | Jefferies | Hold |
| Jan-05-21 | Initiated | William Blair | Outperform |
View All
Certara Inc Stock (CERT) Latest News
Proficio Capital Partners LLC Takes Position in Certara, Inc. (NASDAQ:CERT) - Defense World
Certara at Barclays Healthcare: Strategic Shift Toward Biosimulation - Investing.com
Certara at Barclays Healthcare: Strategic Shift Toward Biosimulation By Investing.com - Investing.com UK
Certara Inc (NASDAQ: CERT) – Analysts’ Revisions Point To Positive Sentiment - Stocks Register
Certara’s SWOT analysis: ai-driven biosimulation firm faces growth challenges - Investing.com India
Bank of New York Mellon Corp Purchases 1,253,385 Shares of Certara, Inc. (NASDAQ:CERT) - Defense World
23,568 Shares in Certara, Inc. (NASDAQ:CERT) Acquired by Private Advisor Group LLC - Defense World
Certara, Inc. (CERT): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts - Insider Monkey
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions - citybiz
Certara announces leadership change in drug development By Investing.com - Investing.com South Africa
Certara announces leadership change in drug development - Investing.com India
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions -March 05, 2025 at 05:07 pm EST - Marketscreener.com
Certara Announces Leadership Change with Dr. Smith’s Departure - TipRanks
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions -March 05, 2025 at 04:16 pm EST - Marketscreener.com
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions -March 05, 2025 at 04:15 pm EST - Marketscreener.com
Can This Former IQVIA Executive Transform Certara's Drug Development Approach? - StockTitan
Principal Financial Group Inc. Has $5.66 Million Stock Position in Certara, Inc. (NASDAQ:CERT) - Defense World
Objective long/short (CERT) Report - Stock Traders Daily
Q2 Earnings Estimate for Certara Issued By William Blair - Defense World
Certara (NASDAQ:CERT) Price Target Raised to $13.00 - Defense World
Q1 Earnings Estimate for Certara Issued By Leerink Partnrs - Defense World
Rhumbline Advisers Has $2.96 Million Stock Holdings in Certara, Inc. (NASDAQ:CERT) - Defense World
Brokerages Set Certara, Inc. (NASDAQ:CERT) Price Target at $15.42 - Defense World
KeyBanc maintains Overweight rating on Certara shares with $15 target By Investing.com - Investing.com South Africa
KeyBanc maintains Overweight rating on Certara shares with $15 target - Investing.com India
Certara’s Earnings Call Highlights Growth Amid Challenges - TipRanks
Certara, Inc. (NASDAQ:CERT) Q4 2024 Earnings Call Transcript - MSN
Certara, Inc. (CERT) Surpasses Q4 Earnings and Revenue Estimates - MSN
TD Cowen Initiates Coverage on Certara With Buy Rating, $16 Price Target -February 27, 2025 at 08:30 am EST - Marketscreener.com
TD Cowen sets Certara stock Buy rating, $16 target By Investing.com - Investing.com Canada
TD Cowen sets Certara stock Buy rating, $16 target - Investing.com India
Certara initiated with a Buy at TD Cowen - TipRanks
Here's Why Certara (NASDAQ:CERT) Can Manage Its Debt Responsibly - Simply Wall St
Certara reports Q4 adjusted EPS 15c, consensus 13c - TipRanks
CIBC Asset Management Inc Invests $132,000 in Certara, Inc. (NASDAQ:CERT) - Defense World
Certara Inc (CERT) Q4 2024 Earnings Call Highlights: Strong Reve - GuruFocus.com
Certara (CERT) Projected to Post Quarterly Earnings on Thursday - Defense World
Certara Inc (CERT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions - Yahoo Finance
Johnson & Johnson Completes Euro-Denominated Debt Offerings; Certara Reports Q4 2024 Results - Defense World
Berry Global Shareholders Approve Merger, Compensation and Adjournment Proposals; Certara Posts Strong Q4 2024 Results - Defense World
Certara, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Certara, Inc. Reports Strong Q4 2024 Results - TipRanks
Earnings call transcript: Certara Q4 2024 beats expectations with EPS growth - Investing.com India
Earnings call transcript: Certara Q4 2024 beats expectations with EPS growth By Investing.com - Investing.com South Africa
Certara, Inc. SEC 10-K Report - TradingView
Certara Reports Fourth Quarter 2024 Financial Results - The Manila Times
Earnings Flash (CERT) CERTARA Posts Q4 Revenue $100.4M, vs. FactSet Est of $98.9M - Marketscreener.com
How Certara Transformed a $12.5M Loss into $6.6M Profit in Latest Earnings Report - StockTitan
Venturi Wealth Management LLC Raises Stock Holdings in Certara, Inc. (NASDAQ:CERT) - Defense World
New York State Teachers Retirement System Sells 1,100 Shares of Certara, Inc. (NASDAQ:CERT) - Defense World
How to Take Advantage of moves in (CERT) - Stock Traders Daily
Certara Inc Stock (CERT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.19%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):